Skip to main content

Market Overview

Recap: AC Immune Q4 Earnings



Shares of AC Immune (NASDAQ:ACIU) moved higher by 3.4% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were flat 0.00% over the past year to ($0.28), which missed the estimate of ($0.27).

Revenue of $1,044,000 declined by 2.70% from the same period last year, which missed the estimate of $1,400,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

AC Immune hasn't issued any revenue guidance for the time being.

Price Action

Company's 52-week high was at $13.00

Company's 52-week low was at $4.42

Price action over last quarter: Up 58.76%

Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.


Related Articles (ACIU)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at